Key result
Elevated hs-CRP and fibrinogen are associated with CAD presence, while neopterin fails to differentiate severity.
Cross-Sectional (n=225)
Answers are grounded in this paper and cite their sources.
Shows that high-sensitivity CRP and fibrinogen track disease severity in stable coronary artery disease, indicating neopterin offers limited risk stratification value.
Assessment of markers of systemic inflammation, such as acute-phase reactants C-reactive protein (CRP), fibrinogen and ceruloplasmin, sialic acid, a major component of these proteins and neopterin, a specific marker of cellular immune activation, in clinically stable coronary artery disease, may contribute to Staging and risk stratification. These markers were measured in 225 consecutive stable coronary artery disease patients before undergoing coronary angiography. According to their angiographic scores 32 patients were designated as having minor, 34 moderate and 96 severe coronary artery disease. 63 patients with negative angiograms were taken as the angiographic controls. High sensitive-CRP (hs-CRP) and fibrinogen were found to be higher in patients with angiographically established coronary artery disease, than in angiographic controls (p<0.05) and correlated with the severity and extent of disease. Ceruloplasmin and sialic acid concentrations did not differ between patients with and without angiographically cstablished coronary artery disease. Serum neopterin levels were sigificantly higher in patients undergoing coronary angiography than in healthy controls. Neopterin levels were similar between the different subgroups of coronary artery disease, suggesting that neopterin determinations do not contribute to the assessment of the presence and severity of disease in clinically stable patients. In stable angina, serum hs-CRP and plasma fibrinogen levels proved to be more effective than ceruloplasmin, sialic acid and neopterin in discriminating between patients with positive and negative angiograms and various degrees of coronary artery disease, thus in pointing out to increased risk. Our results, do not support the inclusion of neopterin in risk assessment of stable coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Gülmen et al. (2004) conducted a cross-sectional in Stable coronary artery disease (n=225). Neopterin and acute-phase reactants (hs-CRP, fibrinogen, ceruloplasmin, sialic acid) vs. Angiographic controls (63 patients with negative angiograms) and healthy controls was evaluated on Presence and angiographic severity of coronary artery disease (p=<0.05). Serum hs-CRP and plasma fibrinogen were significantly higher in angiographically established CAD than in controls (p<0.05), whereas neopterin did not discriminate CAD severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: